帕博利珠单抗致1例患者发生肥厚性苔藓样皮炎和大疱性类天疱疮 - Suppr

Suppr

超能文献

Pembrolizumab-Induced Hypertrophic Lichenoid Dermatitis and Bullous Pemphigoid in One Patient.

作者信息

Alsabbagh Manal, Bava Aneesh, Ansari Sameer

机构信息

Department of Dermatology, King Hamad University Hospital, Busaiteen, Bahrain.

Department of Pathology, King Hamad University Hospital, Busaiteen, Bahrain.

出版信息

Indian Dermatol Online J. 2023 Nov 24;15(3):546-548. doi: 10.4103/idoj.IDOJ_353_23. eCollection 2024 May-Jun.

DOI:10.4103/idoj.IDOJ_353_23

PMID:38845635

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11152489/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0de/11152489/0ded7011c42a/IDOJ-15-546-g001.jpg

相似文献

Pembrolizumab-Induced Hypertrophic Lichenoid Dermatitis and Bullous Pemphigoid in One Patient.

Indian Dermatol Online J. 2023 Nov 24;15(3):546-548. doi: 10.4103/idoj.IDOJ_353_23. eCollection 2024 May-Jun.

Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.

J Oncol Pharm Pract. 2021 Apr;27(3):727-733. doi: 10.1177/1078155220946370. Epub 2020 Aug 9.

Lichenoid erythrodermic bullous pemphigoid of the African patient.

J Am Acad Dermatol. 1998 Nov;39(5 Pt 1):691-7. doi: 10.1016/s0190-9622(98)70040-4.

Bullous Pemphigoid Associated With Pembrolizumab Therapy for Non-Small-Cell Lung Cancer: A Case Report.

Cureus. 2022 Jan 31;14(1):e21770. doi: 10.7759/cureus.21770. eCollection 2022 Jan.

Coexistence of oral mucous membrane pemphigoid and lichenoid drug reaction: a case of toripalimab-triggered and pembrolizumab-aggravated oral adverse events.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 Sep;132(3):e86-e91. doi: 10.1016/j.oooo.2021.05.012. Epub 2021 May 31.

Cutaneous metastases at the sites of pembrolizumab-induced bullous pemphigoid lesions in a patient with melanoma.

Immunotherapy. 2022 Dec;14(17):1377-1382. doi: 10.2217/imt-2022-0113. Epub 2022 Dec 6.

Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature.

Front Med (Lausanne). 2018 Sep 27;5:268. doi: 10.3389/fmed.2018.00268. eCollection 2018.

Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.

Expert Opin Drug Saf. 2019 Jul;18(7):623-633. doi: 10.1080/14740338.2019.1619693. Epub 2019 May 22.

Histology of linear IgA disease, dermatitis herpetiformis, and bullous pemphigoid.

Am J Dermatopathol. 1983 Dec;5(6):547-54. doi: 10.1097/00000372-198312000-00005.

A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report.

SAGE Open Med Case Rep. 2023 Mar 21;11:2050313X231160926. doi: 10.1177/2050313X231160926. eCollection 2023.

引用本文的文献

Hypertrophic Lichen Planus and Hypertrophic Skin Lesions Associated with Histological Lichenoid Infiltrate: A Case Report and Literature Review.

Dermatopathology (Basel). 2025 Feb 25;12(1):8. doi: 10.3390/dermatopathology12010008.

An Adverse Double-Hit by Pembrolizumab: A Case Report of Bullous Pemphigoid and Pneumonitis.

J Med Cases. 2025 Feb;16(2):69-76. doi: 10.14740/jmc5089. Epub 2025 Feb 2.

本文引用的文献

Front Immunol. 2023 Jul 14;14:1175809. doi: 10.3389/fimmu.2023.1175809. eCollection 2023.

Pembrolizumab versus paclitaxel for previously treated, advanced gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized clinical trials.

Medicine (Baltimore). 2022 Dec 2;101(48):e31940. doi: 10.1097/MD.0000000000031940.

Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.

Eur J Cancer. 2021 Mar;145:245-254. doi: 10.1016/j.ejca.2020.12.012. Epub 2021 Jan 5.

How to manage patients with corticosteroids in oncology in the era of immunotherapy?

Eur J Cancer. 2020 Dec;141:239-251. doi: 10.1016/j.ejca.2020.09.032. Epub 2020 Nov 16.

Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study.

Ann Oncol. 2020 Dec;31(12):1764-1772. doi: 10.1016/j.annonc.2020.09.012. Epub 2020 Sep 23.

Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.

J Cutan Pathol. 2020 Oct;47(10):954-959. doi: 10.1111/cup.13739. Epub 2020 Jun 10.

Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience.

Ther Adv Urol. 2019 Apr 4;11:1756287219839285. doi: 10.1177/1756287219839285. eCollection 2019 Jan-Dec.

Pembrolizumab-induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient.

Clin Case Rep. 2019 Mar 11;7(4):773-775. doi: 10.1002/ccr3.2090. eCollection 2019 Apr.

Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14 and CD16 monocytes driving an innate immune response.

J Cutan Pathol. 2019 Sep;46(9):627-636. doi: 10.1111/cup.13454. Epub 2019 Apr 11.

Management of Immunotherapy-Related Toxicities, Version 1.2019.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289. doi: 10.6004/jnccn.2019.0013.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验